Randomized trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Bayer
This is a research study to find out if researchers can lower the chance of your colorectal cancer growing or spreading by using a combination of regorafenib and pembrolizumab compared to pembrolizumab alone.
Enrollment Form
This study is currently enrolling.